Comparing with the 390 million people within the country who are considered at high risk of the disease, the vaccine supply is limited, Liang Wannian, deputy director of the emergency response office of the Ministry of Health, said on Nov 1.

So far, almost 52.9 million doses of the vaccine, which produced by eight domestic manufacturers, have been approved by the top drug authority. According to the ministry’s plans, 65 million people will be inoculated by the end of the year.

Now total cases and fatalities are both increasing sharply, it considered as the pandemic peaked in the country. The mass inoculation program is imperative. The young, seniors and those serving key posts in public service are high-risk group, among who will have the priority to get inoculation.

According to Liang, in China, the peak of the H1N1 pandemic will last until next March, during this period infections and deaths will increase constantly and rapidly.

The H1N1 vaccination is free and voluntary, if possible everyone should get one as soon as possible, he added.

He also said that the vaccine had proven to be safe and effective and so far most of the adverse reactions from injection had been proven mild and temporary.

Just one day before Liang’s warning, Premier Wen Jiabao called upon the tightened measures for H1N1 influenza since the country is faced with a “severe situation”.

During a visit to a children’s hospital in Beijing, Premier Wen said China is faced with daunting challenges to prevent and control of H1N1 and the number of patients infected by the epidemic are likely to have a sharp increase in some areas.

Premier Wen said the country faces a serious work in preventing the spread of the flu strain, appealing to more people on a voluntary basis to be vaccinated while the vaccine production should be raised.

He added it should be encouraged to get vaccinated as early as possible and at the same time the research into and production of vaccines must be progressed.

It is showed in television that Wen with a mask tied over his face, talking with children, parents and people who worked at the hospital.

Medical staff should take care of themselves and avoid infection during the treatments of the patients, he added.

By far, it has reported nearly 45,000 infections in China, including six deaths, the latest was known on Saturday in Heilongjiang province which is in the northeast part of China.

This recent patient was a local adult of the capital Harbin, according to a cryptonym official who is responsible for publicity in the Heilongjiang provincial health department.

It is added by Xinhua News Agency that a cold snap which going to attack on northern China may raise the flu risk up.

But Wen still remains optimism. He believes that the country is fully confident and has the ability to prevent outbreaks. He said that we must do everything we could to reduce the number of serious cases and deaths.

Are you interested in the business opportunities in China?

China is one of the world’s great growth markets and is likely to be for many years to come. Foreign companies often face difficulties in assessing Chinese market demand and enacting effective strategies because of the language barriers, culture differences, and high expense.

BPOVIA is the leading virtual assistant and Knowledge process outsourcing (KPO) service provider in China. BPOVIA is the only virtual assistant company ever been nominated for the prestigious “Red Herring 100 Asia” Awards 2008. Combines international perspective with local know-how, BPOVIA can provide our clients China business development service and help our clients doing successful business in China.

Please visit http://www.BPOVIA.com/ for details about our service.

The vaccine producer Hualan Biological rose 2.47 percent to 57.7 yuan in Shenzhen on Oct 27 while Layn Natural Ingredients rose 2.93 percent to 44.94 yuan.

As Shenzhen Neptunus Bioengineering Co increased 9.24 percent to 15.85 yuan, Zhejiang CONBA Pharmaceutical Co LTD also increased 6.13 percent to 12.12 yuan. China Meheco Corporation closed at 20.98 yuan yesterday, 10 percent up.

The share market also goes well and the five companies’ shares hit the daily limits of 10 percent on Monday.

An industrial analyst Cai Jianjun pointed, the recent gain is mainly underpinned by government orders for vaccines.

China faced a grim situation in containing the disease as the number of cases has risen, said Health Minister Chen Zhu. As of Oct 26, china reported 35,664 H1N1 inflection with 3 deaths, and also in the US President Obama declared that H1N1 a national emergency on Oct 24.

Expert with the ministry of health’s expert panel Xi Xiuming, said there is no reason for any panic but alertness is needed.

Central government has also been massively buying the H1N1 vaccines. And Hualan said it won an order for 11.21 million doses of its flu vaccine from the central government. Beijing Tiantan said it has won an order for 3.02 million doses. Sinovac Biotech received an additional order of 5.19 million.

New York listed company also gained 7.61 percent to close at $8.06 apiese on Monday and all the doses must be delivered by Dec 12.

Cai said that he still feels that the boom in H1N1 vaccine stocks stems largely from speculation, but there are two domestic companies can benefit from the new orders which are Beijing and Tiantan.

Li Yingpeng, the analyst of Galaxy Securities said that this is not the first ever rally of the vaccine sector. Since the H1N1 outbreak in Mexico in March, the pharmaceutical shares have risen many times however, that does not completely reflect their true performance. However for those companies which have won the vaccine orders, there will be substantial improvement in balance sheet. For example, a single dose is priced at 20 yuan, Hualan’s latest order can earn 200 million yuan, which may bring about 100 million yuan of profits.

Are you interested in the business opportunities in China?

China is one of the world’s great growth markets and is likely to be for many years to come. Foreign companies often face difficulties in assessing Chinese market demand and enacting effective strategies because of the language barriers, culture differences, and high expense.

BPOVIA is the leading virtual assistant and Knowledge process outsourcing (KPO) service provider in China. BPOVIA is the only virtual assistant company ever been nominated for the prestigious “Red Herring 100 Asia” Awards 2008. Combines international perspective with local know-how, BPOVIA can provide our clients China business development service and help our clients doing successful business in China.

Please visit http://www.BPOVIA.com/ for details about our service.